ICPT

Ocaliva

Biliary Atresia

Phase 2

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

Catalyst Events

  • TBA


Clinical Trial

  • 2014-004693-42: A Multicenter, Randomized, Open Label, Single- and Multiple-Dose, Dose Finding Study and Open-Label Extension to Assess the Effects of Obeticholic Acid in Pediatric Subjects with Biliary Atresia

Time Line

Related Links

Prior Work



HC updated 5/21/20

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Trilaciclib NDA Filing (GTHX)...

We are fans of GTHX and hope things go well. But we are worried if NDA for Trilaciclib in NSCLC is accepted and accelerated date is set, that expedited PDUFA is too rushed for FDA during a pandemic. S...

ICPT CRL for Ocaliva
...

Intercept Pharmaceuticals, Inc. received a Complete Response Letter from the U.S. FDA for the NDA for Ocaliva which is used for Adult nonalcoholic steatohepatitis (NASH). The FDA stated that the CRL w...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon